Request Trial
HenadziPechan / Shutterstock.com
25 August 2026NewsRegulation & IndustryMarisa Woutersen

The buyers' wishlist: What makes a life sciences deal stack up?

While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal. 

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech
5 October 2026   Tapio Blanc, chief trademark officer at Roche, explains why fighting fakes can be a matter of life and death, and how AI, online platforms, and ‘mousetrap buys’ are affecting brand protection.
Regulation & Industry
5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?
1 October 2026   LSPN Europe made its Basel debut, and two days of conversations showed just how much is changing for life sciences professionals—both in how they work and what they are being asked to do. Marisa Woutersen tallies up the talking points.
Regulation & Industry
Westlaw publisher scores landmark AI copyright win in US appeals court
30 September 2026   The Third Circuit has upheld Thomson Reuters’ victory over Ross Intelligence in the first US appellate ruling on whether AI training can qualify as fair use. With the court’s reasoning still sealed, the case could have significant implications for AI developers using copyrighted content to build competing products.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026

More features

Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech
What's AI best at? In-house teams are still learning
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?
Lilly loses Fed Circ rehearing bid, sparking enablement questions
Westlaw publisher scores landmark AI copyright win in US appeals court
Scientist and Chinese biotech targeted by Beam in secrets suit
Clifford Chance recruits new head of Asia-Pac